Compare Stocks

→ World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALBO Albireo Pharma	$44.15 -0.2%	$44.17	$16.02 ▼ $45.23	$913.91M	1.03	704,539 shs	1.24 million shs
AVTE Aerovate Therapeutics	$21.57 +1.7%	$24.60	$9.41 ▼ $32.42	$600.94M	1.23	132,878 shs	119,830 shs
FLXN Flexion Therapeutics	$9.12	$9.20	$4.30 ▼ $13.66	$458.93M	1.53	1.18 million shs	N/A
VERA Vera Therapeutics	$38.69 -3.2%	$43.24	$6.07 ▼ $50.78	$2.11B	1.05	1.29 million shs	847,246 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALBO Albireo Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
AVTE Aerovate Therapeutics	-8.70%	-5.78%	-21.34%	+15.53%	+12.95%
FLXN Flexion Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
VERA Vera Therapeutics	+1.09%	-0.15%	-2.99%	+57.84%	+531.12%

The Gold Grab of the Century (Ad)

When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALBO Albireo Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	1.4473 of 5 stars	3.5	1.0	0.0	0.0	3.0	1.7	0.0
FLXN Flexion Therapeutics	0.2938 of 5 stars	0.0	0.0	0.0	4.3	0.0	1.7	0.6
VERA Vera Therapeutics	0.8746 of 5 stars	1.5	2.0	0.0	0.0	2.4	5.0	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALBO Albireo Pharma	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	3.00	Buy	$49.33	128.71% Upside
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	3.00	Buy	$32.29	-16.55% Downside

Current Analyst Ratings

Latest FLXN, AVTE, ALBO, and VERA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/5/2024	VERA Vera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$56.00
4/4/2024	AVTE Aerovate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/1/2024	AVTE Aerovate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$35.00
3/27/2024	VERA Vera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $56.00
3/25/2024	AVTE Aerovate Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$21.00 ➝ $65.00
3/21/2024	VERA Vera Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$21.00 ➝ $34.00
1/26/2024	VERA Vera Therapeutics	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Strong-Buy	$29.00 ➝ $37.00
1/26/2024	VERA Vera Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$16.00 ➝ $21.00
1/25/2024	VERA Vera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$26.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALBO Albireo Pharma	$40.58M	22.52	N/A	N/A	$9.11 per share	4.85
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
FLXN Flexion Therapeutics	$85.55M	5.36	N/A	N/A	($0.34) per share	-26.82
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$1.94 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALBO Albireo Pharma	-$34.03M	-$6.72	N/A	N/A	N/A	-228.51%	-97.13%	-46.89%	N/A
AVTE Aerovate Therapeutics	-$75.52M	-$2.88	N/A	N/A	N/A	N/A	-61.62%	-55.08%	5/20/2024 (Estimated)
FLXN Flexion Therapeutics	-$113.71M	-$2.01	N/A	N/A	N/A	-100.32%	N/A	-44.26%	N/A
VERA Vera Therapeutics	-$95.99M	-$2.29	N/A	N/A	N/A	N/A	-73.33%	-50.79%	5/9/2024 (Estimated)

Latest FLXN, AVTE, ALBO, and VERA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/25/2024	Q4 2023	AVTE Aerovate Therapeutics	-$0.68	-$0.74	-$0.06	-$0.74	N/A	N/A
3/20/2024	Q4 2023	VERA Vera Therapeutics	-$0.53	-$0.58	-$0.05	-$0.58	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALBO Albireo Pharma	N/A	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALBO Albireo Pharma	N/A	6.32	6.23
AVTE Aerovate Therapeutics	N/A	7.04	7.04
FLXN Flexion Therapeutics	N/A	4.38	4.05
VERA Vera Therapeutics	0.49	7.71	7.71

Ownership

Institutional Ownership

Company	Institutional Ownership
ALBO Albireo Pharma	94.25%
AVTE Aerovate Therapeutics	N/A
FLXN Flexion Therapeutics	90.01%
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
ALBO Albireo Pharma	6.90%
AVTE Aerovate Therapeutics	19.30%
FLXN Flexion Therapeutics	9.13%
VERA Vera Therapeutics	21.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALBO Albireo Pharma	130	20.70 million	19.27 million	Optionable
AVTE Aerovate Therapeutics	51	27.86 million	22.48 million	Not Optionable
FLXN Flexion Therapeutics	257	50.32 million	45.73 million	Optionable
VERA Vera Therapeutics	51	54.45 million	42.64 million	Optionable

FLXN, AVTE, ALBO, and VERA Headlines

Source	Headline
	Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Buy" from Analysts americanbankingnews.com - April 21 at 2:12 AM
	Rusfertide Shows Promise in Polycythemia Vera renalandurologynews.com - April 17 at 10:25 PM
	Vera Therapeutics (NASDAQ:VERA) Trading Down 3% on Insider Selling americanbankingnews.com - April 16 at 1:26 AM
	Vera Therapeutics (NASDAQ:VERA) Shares Down 3% After Insider Selling marketbeat.com - April 15 at 10:35 AM
	Vera Therapeutics executive sells over $228k in company stock investing.com - April 14 at 9:09 AM
	Vanguard Group Inc. Raises Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA) marketbeat.com - April 14 at 4:16 AM
	What about the company Vertex didn’t buy? statnews.com - April 13 at 7:39 PM
	Insider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Sells 5,714 Shares of Stock insidertrades.com - April 13 at 7:09 AM
	Could This Stock Be the Next Biotech Buyout? fool.com - April 13 at 5:29 AM
	Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ... finance.yahoo.com - April 12 at 10:56 PM
	Joseph R. Young Sells 5,714 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock marketbeat.com - April 12 at 6:34 PM
	Vertex wagers $4.9bn on Alpine kidney disease therapy pharmaphorum.com - April 11 at 8:49 PM
	Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options msn.com - April 11 at 8:49 PM
	2 Biotech Stocks Driving the Nasdaq Today schaeffersresearch.com - April 11 at 1:41 PM
	Vera Therapeutics (NASDAQ:VERA) Stock Price Up 7.2% marketbeat.com - April 10 at 3:24 PM
	Alpine Immune jumps on report of takeover interest msn.com - April 10 at 1:24 PM
	Vera Therapeutics (NASDAQ:VERA) Shares Gap Down on Insider Selling marketbeat.com - April 8 at 10:24 AM
	Vera Therapeutics, Inc. (NASDAQ:VERA) CFO Sells $3,954,187.08 in Stock insidertrades.com - April 8 at 4:24 AM
	Posttransplant Skin Disease: Consider Skin Cancer, Infection Risks medscape.com - April 7 at 8:24 PM
	Commit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using Options nasdaq.com - April 7 at 3:24 PM
	Sean Grant Sells 99,828 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock marketbeat.com - April 6 at 12:37 AM
	Guggenheim Reiterates Buy Rating for Vera Therapeutics (NASDAQ:VERA) marketbeat.com - April 5 at 11:10 AM
	Vera Therapeutics (NASDAQ:VERA) Shares Down 5.9% marketbeat.com - April 3 at 4:28 PM
	Vera Therapeutics: Waiting For A Pullback seekingalpha.com - April 3 at 1:38 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Albireo Pharma

NASDAQ:ALBO

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Aerovate Therapeutics

NASDAQ:AVTE

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Flexion Therapeutics

NASDAQ:FLXN

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Vera Therapeutics

NASDAQ:VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial